Larazotide acetate is a zonulin antagonist (tight-junction regulator). It is filed in this library under digestive & weight, a navigation topic rather than a statement of where it acts. As a regulatory matter it is being studied in clinical trials and is not approved by the FDA.
Regulatory status
Larazotide acetate is investigational.
It has not been approved by the FDA for any use.
ClinicalTrials.gov lists 5 registered studies for it.
The evidence
2 sources on Larazotide acetate published between 2021 and 2022, each resolved to its journal of record. Titles are listed so you can judge the evidence rather than take a summary on trust.
Nearby
Before any compound, the useful question is what your bloodwork already says. The OPTML Score reads a full panel against optimal ranges.
See the OPTML ScoreEducational reference only. This page explains what has been published about Larazotide acetate. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides